Authors: Ponti G, Roli L, Oliva G, Manfredini M, Trenti T, Kaleci S et al. doi: https://doi.org/10.1515/cclm-2021-0168 Abstract The Covid-19 pandemic is a global challenge, with rapidly increasing cases from the high infective aetiological agent, the Covid-19 virus. In October 2020, over 48 million confirmed Covid-19 cases and one million deaths were confirmed (www.who.int). There [...]

Authors: Geerts M, de Greef BT, Sopacua M, Faber CG PMID: 33766992 PMCID: PMC8205474 DOI: 10.1212/WNL.0000000000011919 Abstract Objective: This is the first double-blind randomized controlled trial evaluating the efficacy and safety of IV immunoglobulin (IVIG) vs placebo in patients with idiopathic small fiber neuropathy (I-SFN). Methods: Between July 2016 and November 2018, 60 Dutch patients [...]

Auhtors: Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, et al. PMID: 33842335 PMCID: PMC8027241 DOI: 10.3389/fonc.2021.629666 Abstract Metabolic syndrome is a type of multifactorial metabolic disease with the presence of at least three factors: obesity, diabetes mellitus, low high-density lipoprotein, hypertriglyceridemia, and hypertension. Recent studies have shown that metabolic syndrome [...]

Authors: Classen JB Abstract Many have argued that the outbreak of COVID-19 is the result of the release of a viral based bioweapon. Vaccines to COVID-19 have been developed and a policy of universal immunization has been initiated with total disregard to the fact that the virus may be a bioweapon. The potential risk [...]

Authors: Idrees D, Kumar V PMID: 33789211 PMCID: PMC7988450 DOI: 10.1016/j.bbrc.2021.03.100 Abstract The post-infection of COVID-19 includes a myriad of neurologic symptoms including neurodegeneration. Protein aggregation in brain can be considered as one of the important reasons behind the neurodegeneration. SARS-CoV-2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) binds to heparin and heparin [...]

Authors: Janiaud P, Axfors C, Schmitt AM, Glory V, Moher D PMID: 33635310 PMCID: PMC7911095 DOI: 10.1001/jama.2021.2747 Abstract Importance: Convalescent plasma is a proposed treatment for COVID-19. Objective: To assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care in peer-reviewed and preprint publications or press releases of randomized clinical trials (RCTs). [...]

Authors:Nain Z, Rana HK, Lio P, Islam SM, Summers MA, Moni MA. PMID: PMC7454314 DOI: 10.1093/bib/bbaa173 Abstract The novel coronavirus (2019-nCoV) has recently emerged, causing COVID-19 outbreaks and significant societal/global disruption. Importantly, COVID-19 infection resembles SARS-like complications. However, the lack of knowledge about the underlying genetic mechanisms of COVID-19 warrants the development of prospective control [...]

Authors: Jalali F, Rezaie S, Rola P, Kyle-Sidell C doi: http://dx.doi.org/10.2139/ssrn.3800402 Abstract Established evidence suggests that in ARDS, platelets may exhibit a dysregulated state that exacerbates lung injury. We review evidence that suggests this platelet-mediated lung injury, while present in ARDS in general, is amplified in COVID-19 ARDS in particular. Driven by a quantifiably higher [...]

Authors: Patidar GK, Land KJ, Vrielink H, Dann EJ, Spitalnik SL PMID: 33730761 PMCID: PMC8250601 DOI: 10.1111/vox.13067 Abstract Background and objectives: Cytokine release syndrome in COVID-19 is due to a pathological inflammatory response of raised cytokines. Removal of these cytokines by therapeutic plasma exchange (TPE) prior to end-organ damage may improve clinical outcomes. This manuscript [...]

Authors: Hong SK, Kim HJ, Song CS, Choi IS, Lee JB PMID: 22430099 DOI: 10.1016/j.intimp.2012.03.002 Abstract Suppression of interleukin (IL)-6 production has beneficial effects against various inflammatory diseases. Through a rapid screening system, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, which is a well-known antiparasitic agent, suppressed lipopolysaccharide (LPS)-induced production of IL-6 from RAW 264.7 [...]